JP2022512401A5 - - Google Patents

Info

Publication number
JP2022512401A5
JP2022512401A5 JP2021533540A JP2021533540A JP2022512401A5 JP 2022512401 A5 JP2022512401 A5 JP 2022512401A5 JP 2021533540 A JP2021533540 A JP 2021533540A JP 2021533540 A JP2021533540 A JP 2021533540A JP 2022512401 A5 JP2022512401 A5 JP 2022512401A5
Authority
JP
Japan
Prior art keywords
antibody
seq
linker
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533540A
Other languages
English (en)
Japanese (ja)
Other versions
JP7570329B2 (ja
JP2022512401A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066029 external-priority patent/WO2020123836A2/en
Publication of JP2022512401A publication Critical patent/JP2022512401A/ja
Publication of JP2022512401A5 publication Critical patent/JP2022512401A5/ja
Priority to JP2024176340A priority Critical patent/JP2025020131A/ja
Application granted granted Critical
Publication of JP7570329B2 publication Critical patent/JP7570329B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533540A 2018-12-13 2019-12-12 ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 Active JP7570329B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024176340A JP2025020131A (ja) 2018-12-13 2024-10-08 ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862779400P 2018-12-13 2018-12-13
US201862779406P 2018-12-13 2018-12-13
US62/779,406 2018-12-13
US62/779,400 2018-12-13
US201962941220P 2019-11-27 2019-11-27
US62/941,220 2019-11-27
PCT/US2019/066029 WO2020123836A2 (en) 2018-12-13 2019-12-12 Herboxidiene splicing modulator antibody-drug conjugates and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024176340A Division JP2025020131A (ja) 2018-12-13 2024-10-08 ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022512401A JP2022512401A (ja) 2022-02-03
JP2022512401A5 true JP2022512401A5 (enExample) 2022-12-19
JP7570329B2 JP7570329B2 (ja) 2024-10-21

Family

ID=69160369

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533540A Active JP7570329B2 (ja) 2018-12-13 2019-12-12 ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
JP2024176340A Pending JP2025020131A (ja) 2018-12-13 2024-10-08 ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024176340A Pending JP2025020131A (ja) 2018-12-13 2024-10-08 ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法

Country Status (18)

Country Link
US (1) US12514928B2 (enExample)
EP (1) EP3893937A2 (enExample)
JP (2) JP7570329B2 (enExample)
KR (1) KR20210102274A (enExample)
CN (2) CN120189526A (enExample)
AU (1) AU2019397062A1 (enExample)
BR (1) BR112021010936A2 (enExample)
CA (1) CA3114931A1 (enExample)
CL (4) CL2021001534A1 (enExample)
CO (1) CO2021006503A2 (enExample)
IL (1) IL283787A (enExample)
JO (1) JOP20210045A1 (enExample)
MX (3) MX2021005878A (enExample)
PE (1) PE20211473A1 (enExample)
PH (1) PH12021551389A1 (enExample)
SG (1) SG11202102419VA (enExample)
TW (2) TW202519271A (enExample)
WO (1) WO2020123836A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12172986B2 (en) 2018-06-01 2024-12-24 Eisai R&D Management Co., Ltd Splicing modulator antibody-drug conjugates and methods of use
US11998544B2 (en) 2018-06-01 2024-06-04 Eisai R&D Management Co., Ltd. Methods of using splicing modulators
PE20211473A1 (es) 2018-12-13 2021-08-05 Eisai Randd Man Co Ltd Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso
CN114729042B (zh) 2019-11-07 2026-03-03 卫材R&D管理有限公司 抗间皮素艾日布林抗体-药物缀合物及使用方法
AU2021284401A1 (en) 2020-06-05 2023-01-05 Eisai R&D Management Co., Ltd. Anti-BCMA antibody-drug conjugates and methods of use
TW202233187A (zh) 2020-11-04 2022-09-01 日商衛材R&D企管股份有限公司 骨髓發育不良症候群(mds)之生物標記物及其使用方法
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
JP2025517430A (ja) * 2022-05-20 2025-06-05 ノバルティス アーゲー Epha2 bcl-xl阻害剤抗体-薬物コンジュゲートおよびその使用の方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP1281718A3 (en) 1995-11-10 2005-01-19 ELAN CORPORATION, Plc Peptides which enhance transport across tissues
EP0871490B1 (en) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
AU703922B2 (en) 1995-12-28 1999-04-01 Kyowa Hakko Kogyo Co. Ltd. Compound gexi
JP3795604B2 (ja) * 1995-12-28 2006-07-12 協和醗酵工業株式会社 Gex1化合物
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
ES2321065T3 (es) 2001-04-26 2009-06-02 Biogen Idec Ma Inc. Anticuerpos bloqueantes de cripto y usos de los mismos.
JP4452787B2 (ja) * 2003-03-11 2010-04-21 アステラス製薬株式会社 新規発酵生産物
EP1716179A2 (en) 2004-02-12 2006-11-02 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
AU2006287416A1 (en) 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
AU2007308792B2 (en) 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8512995B2 (en) 2008-06-04 2013-08-20 Eisai R&D Management Co., Ltd. DNA encoding polypeptide involved in biosynthesis of herboxidiene
JPWO2011074621A1 (ja) 2009-12-18 2013-04-25 株式会社医学生物学研究所 メソセリン(msln)に対する抗体及びその用途
EP3925627A1 (en) 2012-05-15 2021-12-22 Concortis Biosystems, Corp Drug-conjugates and uses thereof
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US20140069822A1 (en) 2012-09-10 2014-03-13 Antec Leyden B.V. Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
ES2656298T3 (es) * 2012-11-05 2018-02-26 Pfizer Inc. Análogos de ayustoestatina
US9909128B2 (en) 2012-11-15 2018-03-06 The Regents Of The University Of California Splice modulating oligonucleotides that inhibit cancer
GB201312318D0 (en) 2013-07-09 2013-08-21 Isomerase Therapeutics Ltd Novel methods and compounds
CA2924398A1 (en) 2013-11-05 2015-05-14 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
EP3071563B1 (en) 2013-11-19 2023-04-19 Purdue Research Foundation Anti-cancer agents and preparation thereof
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
MA45280B1 (fr) 2016-03-02 2021-08-31 Eisai R&D Man Co Ltd Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
US11203588B2 (en) * 2016-03-10 2021-12-21 The Regents Of The University Of California Anti-cancer and splice modulating compounds and methods
US11485792B2 (en) 2016-06-06 2022-11-01 Polytherics Limited Antibodies, uses thereof and conjugates thereof
US11584754B2 (en) 2016-06-08 2023-02-21 William Marsh Rice University Derivatives of thailanstatin A, methods of treatment and methods of synthesis thereof
US20200046696A1 (en) 2017-02-14 2020-02-13 Celgene Corporation Treatment of cancer with smg1-inhibitors
AU2018235940A1 (en) 2017-03-15 2019-10-17 Eisai R&D Management Co., Ltd. Spliceosome mutations and uses thereof
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
US11807631B2 (en) * 2017-07-26 2023-11-07 Purdue Research Foundation Herboxidiene derivatives and uses thereof
US11998544B2 (en) 2018-06-01 2024-06-04 Eisai R&D Management Co., Ltd. Methods of using splicing modulators
US12172986B2 (en) 2018-06-01 2024-12-24 Eisai R&D Management Co., Ltd Splicing modulator antibody-drug conjugates and methods of use
PE20211473A1 (es) 2018-12-13 2021-08-05 Eisai Randd Man Co Ltd Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso
CN114729042B (zh) 2019-11-07 2026-03-03 卫材R&D管理有限公司 抗间皮素艾日布林抗体-药物缀合物及使用方法
WO2021148003A1 (zh) 2020-01-22 2021-07-29 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
AU2021284401A1 (en) 2020-06-05 2023-01-05 Eisai R&D Management Co., Ltd. Anti-BCMA antibody-drug conjugates and methods of use

Similar Documents

Publication Publication Date Title
JP2021532063A5 (enExample)
US20210309758A1 (en) Antibodies to muc16 and methods of use thereof
KR102023496B1 (ko) 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
JP5925684B2 (ja) 抗gcc分子と関連組成物および方法
RU2018134331A (ru) Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения
KR20230038738A (ko) 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
JP2020019787A5 (enExample)
JP7570329B2 (ja) ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
ES2818575T3 (es) Reducción selectiva de anticuerpos con modificación de cisteínas
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP2016518382A (ja) Axl抗体薬物複合体および癌の治療のためのその使用
JP2023500875A5 (enExample)
TWI878186B (zh) 新型抗cd19抗體
JP2018529646A (ja) 抗体薬物複合体における共有結合リンカー、並びにその製造方法及び使用方法
JP2018523471A5 (enExample)
TR201908761T4 (tr) Antidll3-antikor-pbd konjugatları ve kullanımları.
RU2016117810A (ru) Конъюгаты белок-полимер-лекарственное средство
JP2024167209A (ja) ツブリシン及びタンパク質-ツブリシンコンジュゲート
JP7827624B2 (ja) 抗cea抗体-エキサテカン類似体複合体及びその医薬用途
US20250121088A1 (en) Anti-muc1* antibody drug complexes and uses thereof
JP2023549925A5 (enExample)
KR20230078152A (ko) Psma에 특이적으로 결합하는 항체 및 그의 용도
JP2016511257A (ja) 癌の治療における抗gcc抗体−薬物複合体及びdna損傷剤の投与
WO2025036480A1 (zh) 化合物以及含有该化合物的抗体偶联药物
RU2024115226A (ru) Конъюгаты антитела и лекарственного средства, содержащие модулятор сплайсинга на основе гербоксидиена, и способы их применения